STAT

What we heard at CRISPRCon: talk of designer babies, IP battles, and scientific colonialism

Here's what we picked up on at #CRISPRCon, the second annual geek-out over the groundbreaking technology.

BOSTON — While lacking the costuming of Comic-Con or revelry of SantaCon, CRISPR’s second annual geek-out dealt with a concept weightier than superheroes or public drunkenness: How should society deal with a technology that can literally reshape the world?

CRISPRcon brought hundreds of academics, industry scientists, and public health officials to Boston this week to answer just that question, moving past the beaker-and-pipette specifics of gene-editing to tackle the ethical, cultural, and democratic implications of science’s favorite new toy.

The event runs through Tuesday. Here are four things we learned on day one.

The ethics of genome-editing is still an open question

If you get a bunch of people in a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.

Related Books & Audiobooks